首页|Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis
Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis
扫码查看
点击上方二维码区域,可以放大扫码查看
原文链接
NETL
NSTL
万方数据
维普
AIM:To investigate the correlation between expression of phosphatase and tensin homolog (PTEN) and cetuximab effects in colorectal cancer.METHODS:We searched PubMed,EMBASE and ASCO to identify eligible studies.Finally,8 randomized control studies were included in the meta-analysis.STATA 10.0 Software was used to investigate heterogeneity among individual studies and to summarize all the studies.Risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the strength of the association.RESULTS:Compared with 20 of 266 patients with loss of PTEN,206 of 496 patients with intact PTEN protein expression had a better objective response rate to cetuximab-based therapy (RR,4.75; 95% CI,2.59-8.72;P < 0.001).PTEN positivity was associated with better progression-free survival (PFS) (HR,0.675; 95% CI,0.473-0.964; P =0.031) but not with better overall survival (OS) (HR,0.608; 95% CI,0.411-0.899; P =0.013).In patients with KRAS wild-type status,PTEN positivity did not predict a longer PFS or OS (PFS:HR,0.707;95% CI,0.440-1.138; P =0.154; OS:HR,0.943; 95%CI,0.646-1.377; P =0.761).CONCLUSION:Expression of PTEN is related to the effect of cetuximab in colorectal cancer patients and should be considered in treatment with cetuximab.
Phosphatase and tensin homologCetuximabColorectal cancerPrognosisMeta-analysis